Cue Biopharma Advances CUE-221 Toward Phase 2 Data
BOSTON, Aug. 14, 2026 Cue Biopharma, Inc. reported continued progress across its clinical-stage pipeline, highlighted by the recent Investigational...
food allergy
Advertisement
DBV Technologies Works With FDA to Finalize VIASKIN Peanut BLA
CHÂTILLON, France, June 29, 2026 DBV Technologies announced an update on the Biologics License Application (BLA) for its investigational...
DBV Technologies Reports Positive VITESSE Data for VIASKIN Peanut Patch
CHÂTILLON, France, June 8, 2026 DBV Technologies announced new positive clinical findings from its Phase 3 VITESSE study evaluating...
Novartis Showcases Rhapsido Data at EAACI 2026
BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...
Kashiv BioSciences Moves Closer to Launching XOLAIR Biosimilar in Canada
PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...
Advertisements
DBV Technologies Screens First Infant in THRIVE Peanut Allergy Study
CHÂTILLON, France and WARREN, N.J., June 2026 DBV Technologies announced that the first participant has been screened in the...
Mabylon Reports Positive Phase Ia MY006 Peanut Allergy Results
SCHLIEREN/ZURICH, Switzerland, May 19, 2026 Mabylon AG announced positive preliminary Phase Ia clinical data for its lead investigational therapy...
Novartis Acquires Excellergy in $2B Allergy Innovation Deal
Basel, Switzerland | March 27, 2026 Strategic Acquisition Strengthens Allergy Leadership Novartis has announced a major strategic move to...
GSK Acquires RAPT in $2.2B Bet on Food Allergy Therapy
London, United Kingdom, January 21, 2026 — GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, securing global...
Advertisement
